Dzintra L.
- Country
- Latvia
- Department
- Kurzeme Urology Center
Research Overview
- Phase 3 Randomized Open-label Study of Opevesostat Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- Phase 3 Randomized Study of Tebipenem Pivoxil Hydrobromide vs. Imipenem-Cilastatin in Complicated Urinary Tract Infection and Acute Pyelonephritis
- Evaluation of BT8009 Monotherapy and BT8009 with Pembrolizumab Versus Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Data & Insights
Has run more than one trial at 49 of 212 partner sites.
Specializations
Prostate Cancer Research
The investigator specializes in treating metastatic castration-resistant prostate cancer, exploring innovative therapeutic approaches for advanced stages of the disease.
- Advanced prostate cancer management
- Hormonal therapy resistance
- Novel therapeutic agents
Their work focuses on evaluating treatment options for patients who have progressed after initial hormonal therapy.
Urothelial Cancer Studies
The investigator conducts research in locally advanced and metastatic urothelial cancer, investigating combination therapy approaches and novel treatment strategies.
- Immunotherapy combinations
- Advanced bladder cancer treatment
- Targeted therapy approaches
Their research encompasses both monotherapy and combination treatment strategies for urothelial cancer.
Bladder Cancer Innovation
The investigator explores treatments for non-muscle invasive bladder cancer, with particular attention to low-grade disease variants and novel therapeutic formulations.
- Novel formulation development
- Low-grade NMIBC treatment
- Tumor ablation approaches
Their work involves evaluating innovative therapeutic solutions for bladder cancer management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.